• Je něco špatně v tomto záznamu ?

The effects of diuretic deprescribing in adult patients: A systematic review to inform an evidence-based diuretic deprescribing guideline

E. van Poelgeest, L. Paoletti, S. Özkök, E. Pinar, G. Bahat, V. Vuong, E. Topinková, J. Daams, L. McCarthy, W. Thompson, N. van der Velde

. 2025 ; 91 (1) : 38-54. [pub] 20240808

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, systematický přehled, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002938

In this systematic review, we report on the effects of diuretic deprescribing compared to continued diuretic use. We included clinical studies reporting on outcomes such as mortality, heart failure recurrence, tolerability and feasibility. We assessed risk of bias and certainty of the evidence using the GRADE framework. We included 25 publications from 22 primary studies (15 randomized controlled trials; 7 nonrandomized studies). The mean number of participants in the deprescribing groups was 35, and median/mean age 64 years. In patients with heart failure, there was no clear evidence that diuretic deprescribing was associated with increased mortality compared to diuretic continuation (low certainty evidence). The risk of cardiovascular composite outcomes associated with diuretic deprescribing was inconsistent (studies showing lower risk for diuretic deprescribing, or comparable risk with diuretic continuation; very low certainty evidence). The effect on heart failure recurrence after diuretic deprescribing in patients with diuretics for heart failure, and of hypertension in patients with diuretics for hypertension was inconsistent across the included studies (low certainty evidence). In patients with diuretics for hypertension, diuretic deprescribing was well tolerated (moderate certainty evidence), while in patients with diuretics for heart failure, deprescribing diuretics can result in complaints of peripheral oedema (very low certainty evidence). The overall risk of bias was generally high. In summary, this systematic review suggests that diuretic discontinuation could be a safe and feasible treatment option for carefully selected patients. However, there isa lack of high-quality evidence on its feasibility, safety and tolerability of diuretic deprescribing, warranting further research.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002938
003      
CZ-PrNML
005      
20250206103948.0
007      
ta
008      
250121s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcp.16189 $2 doi
035    __
$a (PubMed)39117602
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a van Poelgeest, Eveline $u Department of Internal Medicine/Geriatrics, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands $u Aging and Later Life, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands $1 https://orcid.org/0000000220215602
245    14
$a The effects of diuretic deprescribing in adult patients: A systematic review to inform an evidence-based diuretic deprescribing guideline / $c E. van Poelgeest, L. Paoletti, S. Özkök, E. Pinar, G. Bahat, V. Vuong, E. Topinková, J. Daams, L. McCarthy, W. Thompson, N. van der Velde
520    9_
$a In this systematic review, we report on the effects of diuretic deprescribing compared to continued diuretic use. We included clinical studies reporting on outcomes such as mortality, heart failure recurrence, tolerability and feasibility. We assessed risk of bias and certainty of the evidence using the GRADE framework. We included 25 publications from 22 primary studies (15 randomized controlled trials; 7 nonrandomized studies). The mean number of participants in the deprescribing groups was 35, and median/mean age 64 years. In patients with heart failure, there was no clear evidence that diuretic deprescribing was associated with increased mortality compared to diuretic continuation (low certainty evidence). The risk of cardiovascular composite outcomes associated with diuretic deprescribing was inconsistent (studies showing lower risk for diuretic deprescribing, or comparable risk with diuretic continuation; very low certainty evidence). The effect on heart failure recurrence after diuretic deprescribing in patients with diuretics for heart failure, and of hypertension in patients with diuretics for hypertension was inconsistent across the included studies (low certainty evidence). In patients with diuretics for hypertension, diuretic deprescribing was well tolerated (moderate certainty evidence), while in patients with diuretics for heart failure, deprescribing diuretics can result in complaints of peripheral oedema (very low certainty evidence). The overall risk of bias was generally high. In summary, this systematic review suggests that diuretic discontinuation could be a safe and feasible treatment option for carefully selected patients. However, there isa lack of high-quality evidence on its feasibility, safety and tolerability of diuretic deprescribing, warranting further research.
650    _2
$a lidé $7 D006801
650    12
$a depreskripce $7 D000069340
650    12
$a diuretika $x škodlivé účinky $x aplikace a dávkování $x terapeutické užití $7 D004232
650    12
$a srdeční selhání $x farmakoterapie $7 D006333
650    _2
$a hypertenze $x farmakoterapie $7 D006973
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a medicína založená na důkazech $7 D019317
650    _2
$a dospělí $7 D000328
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
655    _2
$a přehledy $7 D016454
700    1_
$a Paoletti, Luca $u Pharmacy Department, IRCCS San Raffaele Hospital, Milan, Italy $1 https://orcid.org/0000000151226067
700    1_
$a Özkök, Serdar $u Istanbul Medical Faculty, Department of Internal Medicine, Division of Geriatrics, Capa, Istanbul University, Istanbul, Turkey $1 https://orcid.org/0000000209941152
700    1_
$a Pinar, Ezgi $u Istanbul Medical Faculty, Department of Internal Medicine, Division of Geriatrics, Capa, Istanbul University, Istanbul, Turkey $1 https://orcid.org/0000000317228602
700    1_
$a Bahat, Gülistan $u Istanbul Medical Faculty, Department of Internal Medicine, Division of Geriatrics, Capa, Istanbul University, Istanbul, Turkey $1 https://orcid.org/0000000153439795
700    1_
$a Vuong, Vincent $u Trillium Health Partners, Mississauga, Ontario, Canada $u Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada $1 https://orcid.org/0000000160462264
700    1_
$a Topinková, Eva $u Department of Geriatrics, 1st Faculty of Medicine Charles University, Prague, Czech Republic $u General Faculty Hospital, Prague, Czech Republic $u Faculty of Health and Social Sciences, University of South Bohemia, České Budějovice, Czech Republic $1 https://orcid.org/0000000267864116 $7 nlk20020113720
700    1_
$a Daams, Joost $u Medical Library, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000280254961
700    1_
$a McCarthy, Lisa $u Trillium Health Partners, Mississauga, Ontario, Canada $u Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada $1 https://orcid.org/0000000190871077
700    1_
$a Thompson, Wade $u Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada $1 https://orcid.org/0000000282684092
700    1_
$a van der Velde, Nathalie $u Department of Internal Medicine/Geriatrics, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands $u Aging and Later Life, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands $1 https://orcid.org/0000000264776209
773    0_
$w MED00000858 $t British journal of clinical pharmacology $x 1365-2125 $g Roč. 91, č. 1 (2025), s. 38-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39117602 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103944 $b ABA008
999    __
$a ok $b bmc $g 2262997 $s 1238945
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 91 $c 1 $d 38-54 $e 20240808 $i 1365-2125 $m British journal of clinical pharmacology $n Br J Clin Pharmacol $x MED00000858
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace